Genotoxicity. Meloxicam did not demonstrate genotoxic potential in assays for gene mutation in vitro and chromosomal damage in vitro and in vivo.

alte AINS, inclusiv salicilaţi în doze mari (acid acetilsalicilic): administrarea concomitentă câtorva AINS poate creşte riscul ulceraţiilor şi al sângerărilor gastrointestinale prin efect sinergic. Utilizarea meloxicamului asociat altor AINS nu este recomandată.

Interaction

Anticonceptionalele intra in categoria metodelor contraceptive si reprezinta forma farmaceutica a acestora ce sunt administrate sub forma de pilule sau tablete (comprimate) ori chiar si in forma de unguente sau creme. ulcere ale stomacului sau ale partilor superioare ale intestinului subtire (ulcere peptice/gastro- duodenale); Higher doses of Movalis (22.5 mg and greater) have been associated with an increased risk of serious gastrointestinal tract (GIT) adverse events, therefore, the daily dose of Movalis should not exceed 15 mg.

NSAIDs inhibit prostaglandin synthesis and, when given during the latter part of pregnancy, may cause closure of the fetal ductus arteriosus, fetal renal impairment, inhibition of platelet aggregation and delay of labour and birth. Continuous treatment with NSAIDs during the last trimester of pregnancy should only be given on sound indications. During the last few days before expected birth, agents with inhibitory effects on prostaglandin synthesis should be avoided.

Movalis Alcohol interaction

Poliartrită reumatoidă: 15 mg/zi. În funcţie de răspunsul terapeutic, doza poate fi redusă la 7,5 mg/zi. Spondilită anchilopozantă: 15 mg/zi.